Related Experiment Videos
Mizoribine reduces urinary protein excretion in rats given puromycin aminonucleoside
T Shibasaki1, H Matsuda, H Gomi
1Second Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan.
Abstract:
Mizoribine (MZR), a purine nucleoside antibiotic, is an effective immunosuppressive agent that prevents rejection reactions after kidney transplantation in humans. The present study was performed to examine the effect of MZR on nephrosis produced in rats given puromycin aminonucleoside (PAN). Urinary protein excretion in rats injected with PAN and MZR (PAN + MZR rats) was shown to be reduced significantly in comparison with rats given only PAN (PAN rats). Although mild hypoproteinemia persisted during the experimental period in PAN + MZR rats, no loss of body weight or state of malnutrition was observed. The reduction of serum IgG and C3 was reversed by administration of MZR. Polyethyleinamine (PEI) staining of renal sections showed increased numbers of anionic sites in PAN + MZR rats in comparison with PAN rats, suggesting that MZR improved the permselectivity of the glomerular basement membrane (GBM). Moreover, the production of thromboxane B2 (TxB2) was significantly inhibited in PAN + MZR rats compared with PAN rats. No serious adverse effects of MZR were observed after a large dose of the agent. It is possible that restoration of the charge barrier of the GBM damaged by PAN, or reduction of TxB2 production by the glomeruli may underlie the reduction of protein excretion induced by administration of MZR.
Insights
Mizoribine (MZR) reduces urinary protein loss in nephrotic rats by improving kidney function and decreasing inflammation. This immunosuppressive drug shows promise for treating kidney disease without significant adverse effects.
Area of Science:
- Nephrology
- Immunology
- Pharmacology
Background:
- Mizoribine (MZR) is an immunosuppressive antibiotic used to prevent transplant rejection.
- Puromycin aminonucleoside (PAN)-induced nephrosis is a model for human kidney disease.
Purpose of the Study:
- To investigate the therapeutic effects of MZR on PAN-induced nephrosis in rats.
- To elucidate the mechanisms underlying MZR's action on kidney injury.
Main Methods:
- Rats were induced with nephrosis using PAN, with some receiving MZR treatment.
- Urinary protein excretion, serum protein levels, and IgG/C3 concentrations were measured.
- Renal sections were stained with Polyethyleinamine (PEI) to assess anionic sites.
- Thromboxane B2 (TxB2) production was quantified.
Main Results:
- MZR significantly reduced urinary protein excretion in PAN-induced nephrotic rats.
- MZR administration reversed reductions in serum IgG and C3 levels.
- Increased anionic sites in the glomerular basement membrane (GBM) were observed with MZR treatment.
- MZR significantly inhibited thromboxane B2 (TxB2) production.
Conclusions:
- MZR demonstrates a protective effect against PAN-induced nephrosis in rats.
- MZR may restore the GBM's charge barrier and reduce TxB2 production, mitigating proteinuria.
- MZR is a potential therapeutic agent for nephrotic conditions with a favorable safety profile.